PolandPoland

New CEO after failed deal

21.02.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell its 33.3% stake in Bioton to Jerzy Starak’s Polpharma, the company’s share price went on a rollercoaster ride as shareholders tried to come to grip with the news, swinging up and down by as much as 40% in trading.
The latest news was accompanied by a communiqué detailing the retirement of Bioton CEO Adam Wilczega, who will remain on its board as Vice-President. “The most important issue is to regain the trust of investors,” said new CEO and Board President Janusz R. Guy. Guy declared that he will verify the structure of the company’s portfolio and focus on products that are guaranteed to grow in value.
According to local media, Bioton needs a EUR 20m investment to survive. At the end of January, Prokom Investments – Bioton’s largest investor – agreed to provide a cash injection of approximately a11m until the end of the year.

PolandPoland

09.05.2011

Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross...

PolandPoland

06.04.2011

Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...

PolandPoland

04.04.2011

Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...

PolandPoland

25.02.2011

Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...

PolandPoland

06.02.2011

Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...

PolandPoland

04.11.2010

Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...

PolandPoland

19.09.2010

Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not...

PolandPoland

18.09.2010

Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...

PolandPoland

10.07.2010

Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...

PolandPoland

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/1/article/new-ceo-after-failed-deal-1.html

Product of the week

Products

Events

All Events

Current issue

All issues